PDCD1 and colorectal carcinoma: The use of anti-PD1 antibodies in CRC was initially discouraged, especially after initial studies in PD-1-deficient mice suggesting that PD-1 deficiency increases the incidence of autoimmune diseases [121,122], despite small benefits being obtained.